Osteodystrophy in chronic liver disease
Abstract
Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.
Read the paper
Related studies
- Vitamin D supplementation for improving bone density in vitamin D-deficient children and adolescents: systematic review and individual participant data meta-analysis of randomized controlled trials
- Calcium supplementation during pregnancy and maternal and offspring bone health: a systematic review and meta-analysis
- Change in CT-measured acetabular bone density following total hip arthroplasty: a systematic review and meta-analysis
- Bisphosphonate therapy for osteogenesis imperfecta
- Bisphosphonate therapy for osteogenesis imperfecta
- Exposure to per- and polyfluoroalkyl substances and bone health: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.